Research programme: polycefin therapeutics - Arrogene

Drug Profile

Research programme: polycefin therapeutics - Arrogene

Alternative Names: AG-101; AG-102; AG-103

Latest Information Update: 20 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arrogene
  • Class Antisense oligonucleotides; Biopolymers
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors; Laminin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Breast cancer; Lung cancer

Most Recent Events

  • 25 Apr 2016 Preclinical trials in Lung cancer in USA (IV) before April 2016 (Arrogene 10-K, April 2016)
  • 25 Apr 2016 Arrogene plans to file an IND application with the US FDA for Brain tumours (Arrogene 10-K, April 2016)
  • 25 Apr 2016 Arrogene plans a phase I trial for Brain tumours in USA (Arrogene 10-K, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top